Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “While the Phase 1b data provides evidence that NXP800 is biologically active in recurrent, platinum resistant, ARID1a-mutated ovarian cancer, we have decided to focus our near-term efforts on advancing NXP900.” Mr. Bentsur continued, “Recurrent, platinum resistant, ARID1a-mutated ovarian cancer is a rare and very difficult to treat disease with a dismal prognosis, so while any progress in improving outcomes for these patients is important, the time and resources that we believe will be required to further develop NXP800 in this disease setting led us to make this decision. We thank the investigators and study participants for their involvement in the NXP800 Phase 1b study.” Mr. Bentsur added, “That said, we believe that NXP800 is an active agent and in the coming months we will evaluate the feasibility of other opportunities in which NXP800 can potentially demonstrate its anti-cancer activity more profoundly.” Mr. Bentsur concluded, “We are excited to be at the cusp of initiating the Phase 1b program for NXP900, which will aim to unleash the significant therapeutic potential that we believe is embedded in NXP900.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines